180 related articles for article (PubMed ID: 25706799)
1. 99mTc-HYNIC-TOC imaging in the evaluation of pancreatic masses which are potential neuroendocrine tumors.
Qiao Z; Zhang J; Jin X; Huo L; Zhu Z; Xing H; Li F
Clin Nucl Med; 2015 May; 40(5):397-400. PubMed ID: 25706799
[TBL] [Abstract][Full Text] [Related]
2. Clinical application of
Xu J; Li Y; Xu X; Zhang J; Zhang Y; Yu X; Huang D
Ann Nucl Med; 2018 Aug; 32(7):446-452. PubMed ID: 29926342
[TBL] [Abstract][Full Text] [Related]
3. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors.
Gabriel M; Muehllechner P; Decristoforo C; von Guggenberg E; Kendler D; Prommegger R; Profanter C; Moncayo R; Virgolini I
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):237-44. PubMed ID: 16172569
[TBL] [Abstract][Full Text] [Related]
4. [99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract].
Gómez M; Ferrando R; Vilar J; Hitateguy R; López B; Moreira E; Kapitán M; De Lima F; Agüero B; Gabriela Villegas M; Urdaneta N; Gutiérrez E; Battegazzore A; Bayardo K; Silveira A; Lago G; Páez A
Acta Gastroenterol Latinoam; 2010 Dec; 40(4):332-8. PubMed ID: 21381408
[TBL] [Abstract][Full Text] [Related]
5. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
Cwikla JB; Mikolajczak R; Pawlak D; Buscombe JR; Nasierowska-Guttmejer A; Bator A; Maecke HR; Walecki J
J Nucl Med; 2008 Jul; 49(7):1060-5. PubMed ID: 18552141
[TBL] [Abstract][Full Text] [Related]
6. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
[TBL] [Abstract][Full Text] [Related]
7. Incremental value of
Trogrlic M; Težak S
Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
[TBL] [Abstract][Full Text] [Related]
8. Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors.
Parisella MG; Chianelli M; D'Alessandria C; Todino V; Mikolajczak R; Papini E; Dierckx RA; Scopinaro F; Signore A
Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):90-8. PubMed ID: 21068709
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary clinical application of 99Tcm-HYNIC-TOC imaging in somatostatin receptor-positive tumors].
Li F; Chen LB; Jing HL; Du YR; Chen F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):563-6. PubMed ID: 14650159
[TBL] [Abstract][Full Text] [Related]
10. Microcystic Serous Cystadenoma Masquerading as Pancreatic Neuroendocrine Tumor on 99m Tc-HYNIC-TOC SPECT/CT.
Cai W; Dong Y; Zhao T; Dong A; Zhao Q
Clin Nucl Med; 2024 Feb; 49(2):e87-e89. PubMed ID: 38048519
[TBL] [Abstract][Full Text] [Related]
11. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
12. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
Trogrlic M; Tezak S
Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
[TBL] [Abstract][Full Text] [Related]
13. Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan.
Jing H; Li F; Zhuang H; Wang Z; Tian J; Xing X; Jin J; Zhong D; Zhang J
Eur J Radiol; 2013 Nov; 82(11):2028-34. PubMed ID: 23721625
[TBL] [Abstract][Full Text] [Related]
14. Specificity and sensitivity of ⁹⁹mTc-EDDA/HYNIC-Tyr³-octreotide (⁹⁹mTc-TOC) for imaging neuroendocrine tumors.
Sepúlveda-Méndez J; de Murphy CA; Pedraza-López M; Murphy-Stack E; Rojas-Bautista JC; González-Treviño O
Nucl Med Commun; 2012 Jan; 33(1):69-79. PubMed ID: 21970835
[TBL] [Abstract][Full Text] [Related]
15. Improved kit formulation for preparation of (99m)Tc-HYNIC-TOC: results of preliminary clinical evaluation in imaging patients with neuroendocrine tumors.
Korde A; Mallia M; Shinto A; Sarma HD; Samuel G; Banerjee S
Cancer Biother Radiopharm; 2014 Nov; 29(9):387-94. PubMed ID: 25379612
[TBL] [Abstract][Full Text] [Related]
16. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of
Chen H; Li Y; Gao X; Shen X
Clin Imaging; 2018; 52():365-369. PubMed ID: 30248495
[TBL] [Abstract][Full Text] [Related]
18. Role of 99mTc-HYNIC-Tyr3-octreotide scintigraphy in neuroendocrine tumors based on localization of the primary tumor.
Jimenez Londoño GA; García Vicente AM; Soriano Castrejon AM; Gómez López OV; Palomar Muñoz A; Vega Caicedo CH; Cordero García JM
Minerva Endocrinol; 2016 Mar; 41(1):10-8. PubMed ID: 25582872
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT.
Yamaga LY; Neto GC; da Cunha ML; Osawa A; Oliveira JC; Fonseca RQ; Nogueira SA; Wagner J; Funari MG
Radiol Med; 2016 Mar; 121(3):225-8. PubMed ID: 26558391
[TBL] [Abstract][Full Text] [Related]
20. 99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma.
Chen L; Li F; Zhuang H; Jing H; Du Y; Zeng Z
J Nucl Med; 2009 Mar; 50(3):397-400. PubMed ID: 19223405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
